Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

916
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
916
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

77
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
77
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.4K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.8K
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

311
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCG vaccination mitigates tau pathology and restores cognitive function in PS19 mice.

bioRxiv : the preprint server for biology·2026
Same author

Systematic and quantitative analyses of hollow fiber model of <i>Mycobacterium abscessus</i> lung disease studies and new dosing recommendations.

Microbiology spectrum·2026
Same author

Novel regimens for treatment of <i>Mycobacterium avium</i> lung disease based on advanced <i>in vitro</i> systems and the mathematics of basis functions.

bioRxiv : the preprint server for biology·2026
Same author

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for <i>Mycobacterium abscessus</i> lung disease.

Antimicrobial agents and chemotherapy·2026
Same author

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis.

Nature medicine·2026
Same author

Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.

ACS infectious diseases·2026

Related Experiment Video

Updated: Apr 11, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Nonclinical models for antituberculosis drug development: a landscape analysis.

Tawanda Gumbo1, Anne J Lenaerts2, Debra Hanna3

  • 1Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas Department of Medicine, University of Cape Town, South Africa.

The Journal of Infectious Diseases
|May 27, 2015
PubMed
Summary

Drug-development tools (DDTs) are crucial for tuberculosis treatment research. A combination of models is recommended, but further standardization and validation are needed to predict clinical outcomes effectively.

Keywords:
antituberculosisdrug developmentdrug regimen designguinea pig tuberculosis modelhollow fiber system model of tuberculosismouse tuberculosis model

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Related Experiment Videos

Last Updated: Apr 11, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Area of Science:

  • Tuberculosis Research
  • Pharmacology
  • Drug Development

Background:

  • Nonclinical drug-development tools (DDTs) have been utilized for decades in tuberculosis drug development.
  • The precise role and limitations of existing DDTs for evaluating antituberculosis drug combinations remain unclear.
  • Gaps in evidence highlight the need for novel tools and approaches in antituberculosis drug discovery.

Purpose of the Study:

  • To analyze the landscape of nonclinical drug-development tools (DDTs) for tuberculosis.
  • To identify evidence-based guidelines for the effective use of DDTs in antituberculosis drug development.
  • To define the gaps in current nonclinical models and suggest areas for improvement.

Main Methods:

  • A comprehensive literature review was conducted.
  • A landscape analysis approach was employed to synthesize existing evidence.
  • Evidence-based guidelines were developed from the literature review.

Main Results:

  • Four key DDTs were identified: in vitro susceptibility tests, hollow fiber system model, mice, and guinea pigs.
  • No single nonclinical model fully replicates human tuberculosis; a combination of models is recommended.
  • Identified gaps include the need for standardized experiments, improved animal models, and correlation of experimental output with human sterilizing effects.

Conclusions:

  • Formal quantitative analyses are necessary to assess the predictive accuracy of DDTs for clinical outcomes.
  • Standardization and validation of nonclinical models are critical for reliable antituberculosis drug development.
  • Further research is needed to bridge the gap between nonclinical findings and human clinical efficacy.